English
Segment disclosures
Company overviewVerastem, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
3 dimension combinations 15 retained observations 10 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Product · Research Developing And Commercialization Drugs Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-09-30 | 67761000 | USD | 20261105 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 43749000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 30914000 | USD | 20260304 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 11242000 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 13379000 | USD | 20261105 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 2137000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 2137000 | USD | 20260806 | Open filing evidence |
Copiktra License And Related Assets · Research Developing And Commercialization Drugs Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=vstm:CopiktraLicenseAndRelatedAssetsMember;us-gaap:StatementBusinessSegmentsAxis=vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-09-30 | 15000000 | USD | 20261105 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 15000000 | USD | 20260806 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 10000000 | USD | 20260304 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 10000000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 10000000 | USD | 20250807 | Open filing evidence |
Research Developing And Commercialization Drugs Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=vstm:ResearchDevelopingAndCommercializationDrugsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 18671000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 10000000 | USD | 20250320 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 2596000 | USD | 20250320 | Open filing evidence |